具有和没有维生素K的4因子原胺复合缩剂在管理华法林相关重大出血时的有效性
Şeyma Arzu Temür1, Mustafa Selçuk Ayar2, Yiğit Kurnaz1
1Department of Emergency Medicine, Ondokuz Mayıs University Faculty of Medicine, Samsun, Türkiye.
The Eurasian journal of medicine
|May 16, 2025
概括
与维生素K结合的四因子前列红素复合缩物 (4F-PCC) 在与华法林相关的出血患者中有效控制国际规范化比率 (INR). 与单独使用4F-PCC相比,这种组合显示出更好的INR控制.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 紧急医疗 紧急医疗
背景情况:
- 严重出血是维生素K抗剂 (华法林) 治疗的严重并发症.
- 快速逆转抗凝血是管理急性出血事件的关键.
- 促胺复合物缩剂 (PCC) 为华法林逆转提供了一个有效的选择.
研究的目的:
- 评估使用维生素K和没有维生素K的4因子PCC (4F-PCC) 对于INR控制的疗效.
- 评估因华法林导致危及生命的出血患者的INR管理.
主要方法:
- 对50名与华法林相关出血的患者进行了回顾性横截面研究.
- 患者接受了单独的4F-PCC (第一组) 或4F-PCC加维生素K (第二组).
- 在治疗后24小时,INR水平在各组之间进行了比较.
主要成果:
- 2组 (4F-PCC + 维生素K) 与1组 (4F-PCC 单独) 相比,24小时内INR水平显著降低.
- 在1至24小时之间,在组内没有观察到INR水平的显著差异.
- 这项研究包括了72岁的中年龄患者,主要是男性 (56%),心脏膜疾病 (54%) 是华法林的常见适应症.
结论:
- 4F-PCC和维生素K的联合治疗对INR控制比单独使用4F-PCC更有效.
- 这种组合不会显著影响反弹的INR增加.
- 需要进一步的前性多中心研究来验证发现并评估长期结果.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
570
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
570
01:24Disorders of Hemostasis
664
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
664
01:09Coagulation
3.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
3.8K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
4.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.2K
01:16Clot Retraction and Fibrinolysis
3.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.0K